Basic Information
Ruconest
Regulatory Information
EMEA/H/C/001223
Authorised
October 28, 2010
14
August 30, 2024
Company Information
the netherlands
Darwinweg 24 NL-2333 CR Leiden
Pharming Group
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Ruconest is indicated for treatment of acute angioedema attacks in adults with hereditary angioedema (HAE) due to C1-esterase-inhibitor deficiency.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Ruconest. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ruconest.